High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lee, Hyun ^a   Zhu, Tian ^a   Patel, Kavankumar ^a   Zhang, Yan Yan ^a   Truong, Lena ^a   Hevener, Kirk E ^a,b   Gatuz, Joseph L ^a   Subramanya, Gitanjali ^a,c   Jeong, Hyun Young ^a   Uprichard, Susan L ^a   Johnson, Michael E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VIRUS NS3 INHIBITOR; HEPATITIS C VIRUS NS4A INHIBITOR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ASSAY; FLUORESCENCE; GENOTYPE; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; IC 50; MOLECULAR DOCKING; NONHUMAN; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; VIRUS MUTANT;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; HEPACIVIRUS; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84885110001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075144     Document Type: Article

References (37)

1. Seeff LB, (2002) Natural history of chronic hepatitis C. Hepatology. 36: S35-46.
2. Timm J, Roggendorf M, (2007) Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 13: 4808-4817.
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362.
4. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, et al. (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87: 331-342.
5. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, et al. (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87: 343-355.
6. Cicero DO, Barbato G, Koch U, Ingallinella P, Bianchi E, et al. (1999) Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J Mol Biol 289: 385-396.
7. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM, (2000) Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 74: 2046-2051.
8. Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, et al. (1998) Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 8: 1713-1718.
9. Malancona S, Colarusso S, Ontoria JM, Marchetti A, Poma M, et al. (2004) SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease. Bioorg Med Chem Lett 14: 4575-4579.
10. Melnikova I, (2008) Hepatitis C therapies. Nature Reviews Drug Discovery 7: 799-800.
11. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, et al. (2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132: 1270-1278.
12. Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, et al. (2012) Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 8: 920-925.
13. Yang PL, Gao M, Lin K, Liu Q, Villareal VA, (2011) Anti-HCV drugs in the pipeline. Curr Opin Virol 1: 607-616.
14. Romano KP, Ali A, Royer WE, Schiffer CA, (2010) Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A 107: 20986-20991.
15. Zarkesh-Esfahani SH, Kardi MT, Edalati M, (2010) Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J 7: 69.
16. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, et al. (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19: 1321-1324.
17. Zein NN, (2000) Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13: 223-235.
18. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
19. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492.
20. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444.
21. Cheng JS, Bonis ALP, Lau J, Pham QN, Wong BJ, (2001) Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. Hepatology 33: 231-240.
22. Chaudhuri R, Lee H, Truong L, Torres J, Patel KK, et al. (2012) Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through In-silico Screening. J Chem Inf Model. 52: 2245-2256.
23. Rishton GM, (2003) Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 8: 86-96.
24. Lee H, Torres J, Truong L, Chaudhuri R, Mittal A, et al. (2012) Reducing agents affect inhibitory activities of compounds: Results from multiple drug targets. Anal Biochem 423: 46-53.
25. Jeong H, Chiou WL, (2006) Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica 36: 1-13.
26. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299.
27. Blight KJ, Kolykhalov AA, Rice CM, (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290: 1972-1974.
28. Uprichard SL, Chung J, Chisari FV, Wakita T, (2006) Replication of a hepatitis C virus replicon clone in mouse cells. Virol J 3: 89.
29. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD, (2003) Improved protein-ligand docking using GOLD. Proteins 52: 609-623.
30. Schrodinger (2011) LigPrep, version 2.5. 2.5 ed. New York, NY: Schrodinger, LLC.
31. Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, et al. (2007) Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21: 681-691.
32. Burnham KP, Anderson DR, (2004) Multimodel inference: understanding AIC and BIC in Model Selection. Sociological Methods and Research 33: 261-304.
33. Tan SL, ed (2006) Hepatitis C Viruses: Genomes and Molecular Biology: Horizon Bioscience.
34. Paulson MS, Yang H, Shih IH, Feng JY, Mabery EM, et al. (2009) Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. Antiviral Res 83: 135-142.
35. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, et al. (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426: 186-189.
36. Schiering N, D'Arcy A, Villard F, Simic O, Kamke M, et al. (2011) A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target. Proc Natl Acad Sci U S A 108: 21052-21056.
37. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.